Stories

Steven Brill Jan 25, 2017
SaveSave story

The drug industry’s opinions about its products may soon be protected, too

Rebecca Zisser/Axios

As I wrote yesterday, the drug industry is likely soon to be free of its restrictions on off-label promotions. But it's actually looking at a bigger prize than just sending doctors dense medical journal articles about the potential benefits of off-label uses. It wants to be able to express opinions about its drugs — to doctors and even consumers — and have them be protected as free speech.

If that happens, experts say, watch out — because that gets rid of any incentive to do safety or effectiveness studies at all.